Pascal Sève

TL;DR: This review provides an overview of current knowledge on COVID-19 immunopathology, discussing the defective type-I IFN response, the theoretical role of IL-7 to restore lymphocyte repertoire, as well as reviewing current evidence drawn from clinical trials.

TL;DR: Adult-onset Still's disease cases benefit now from recent insights into autoinflammatory disorders: anakinra seems to be an efficient, well tolerated, steroid-sparing treatment in systemic patterns; tocilizumab seems efficient in AOSD with active arthritis and systemic symptoms while TNFα-blockers could be interesting in chronic polyarticular refractory AOSd.

TL;DR: Analysis of samples from patients in the JBR-10 trial, which compared adjuvant chemotherapy to no further therapy in operable non-small-cell lung cancer, showed that chemotherapy seemed to overcome the negative prognostic effect of high levels of expression of class III beta-tubulin and the greatest benefit from cisplatin/vinorelbine was seen in patients with high levels.

TL;DR: The expression levels of class III β-tubulin in tumor cells is predictive of response to therapy and patient outcome in patients with NSCLC receiving paclitaxel-based chemotherapy but is not a general prognostic factor in this patient population.

TL;DR: The condition in highly symptomatic patients evolved to systemic AOSD, whereas more progressive patterns with arthritis predicted chronic AOSS, and GF and 18FDG-PET scans were of value in the diagnostic approach.